Accuray CyberKnife® Platform Featured in New Studies Showcasing its Benefits in Central Nervous System Tumors Presented at Radiosurgery Society Scientific Meeting

Data Also Highlights Continued Clinical Advances Using the CyberKnife System That are Making
High Quality Care an Option for People Who Previously Had Limited Choices

MADISON, Wis., April 3, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data on the clinical use of the CyberKnife^® System reinforce the device's broad-based radiation treatment capabilities for central nervous system (CNS) tumors. Malignant brain and other CNS tumors are considered to be some of the most fatal types of cancer and contribute to significant morbidity and mortality in the United States ¹. The studies, involving the delivery of stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT), were presented at the recent 2025 Radiosurgery Society (RSS) Scientific Meeting in Tucson, Arizona.

SRS and SBRT are non-surgical procedures that deliver precisely targeted doses of radiotherapy, typically in one to five treatment sessions, with the goal of ablating (destroying) the tumor or lesion. To achieve the accuracy and precision required, the CyberKnife System uses image guidance during treatment, and leverages potentially 1,000 different beam angles targeting the tumor as well as Synchrony^® adaptive delivery, which adjusts the aim of the beam in real time to correct for tumor or patient motion.

"The studies presented at this year's Radiosurgery Society meeting underscore both the long-term efficacy and expanding applications of the CyberKnife System. Whether treating benign tumors like vestibular schwannoma or managing complex conditions such as spinal metastases and trigeminal neuralgia, the common thread is the need for precise, highly targeted radiation delivery — a hallmark of the CyberKnife System. These new data not only reinforce its value in central nervous system treatments but also add to the growing body of evidence supporting its role in improving both the quality and longevity of patients' lives," said Seth Blacksburg, M.D., MBA, Chief Medical Officer at Accuray.

RSS CyberKnife System Study Highlights: Advancing and Expanding Patient Care

25-Year Data Supports the Use of the CyberKnife System to Treat Vestibular Schwannoma (VS)

• 25-year data were reported for patients in a single institution study retrospectively evaluating SRS for the treatment of VS (also known as acoustic neuroma) using the CyberKnife System. A non-cancerous, usually slow-growing brain tumor, VS can cause hearing loss, ringing in the ear, and dizziness or loss of balance. The study demonstrated treatment with the system provides sustained local tumor control and long-term efficacy. At 25 years, the local control rate was 89.3 percent and overall survival was 97.1 percent ².

Clinical Innovation Facilitates Treatment of Challenging Condition Using the CyberKnife System

• A study evaluated the safety and efficacy of donut-shaped circumferential stereotactic body radiation therapy (SBRT) delivered using the CyberKnife System for the treatment of spinal metastases. This treatment technique is designed to target the spinal column while avoiding the spinal cord. High doses of radiation delivered to the spinal cord can result in serious complications, such as radiation myelopathy, causing injury or paralysis. Study investigators concluded, "Donut-shaped circumferential CyberKnife SBRT is a safe and effective treatment for spinal metastases, achieving high local tumor control with minimal radiation-induced complications, including myelopathy ³."

CyberKnife System Expands Treatment Options for Patients with Painful Neurological Conditions
Trigeminal neuralgia and occipital condyle metastasis are rare conditions often causing excruciating pain that may impact all aspects of patients' daily life.

• A study of elderly patients (aged 80 to 100 years) with trigeminal neuralgia found that radiosurgery delivered using the CyberKnife System provides excellent outcomes. Pain improved or disappeared in 90 percent of those evaluated and only three percent developed paresthesia – a sensation of tingling, "pins and needles" or numbness – considered bothersome. Data indicate radiosurgery provides an option for a patient population that may have limited choices because health issues preclude surgery or they are unresponsive to medication⁴.
• An evaluation of SRS for occipital condyle metastasis (OCM) using the CyberKnife System found the treatment offers significant pain relief, excellent local control rates and improvement in neurological symptoms. A 93.8 percent local tumor control rate was achieved over three years. Of patients who reported symptoms, 87.5 percent experienced pain relief. Study authors concluded, "This non-invasive therapy provides a valuable alternative to surgery, potentially enhancing the quality of life for patients with limited treatment options due to this challenging condition⁵."

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to, clinical results, patient experiences and patient outcomes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the company's ability to achieve widespread market acceptance of its products; the company's ability to develop new products or improve existing products to meet customers' needs; the company's ability to anticipate or keep pace with changes in the marketplace and the direction of technological innovation and customer demands and such other risks identified under the heading "Risk Factors" in the company's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission (the "SEC") on February 5, 2025, and as updated periodically with the company's other filings with the SEC. 

Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.

Media Contact:
Beth Kaplan         
Public Relations Director, Accuray                                         
+1 (408) 789-4426                                                                   
[email protected]                                                                             

¹ Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, Fuchs HE, Waite KA, Jemal A, Siegel RL, Barnholtz-Sloan JS. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021 Sep;71(5):381-406. doi: 10.3322/caac.21693. Epub 2021 Aug 24. PMID: 34427324.
² "Long-Term Outcomes of Vestibular Schwannoma Treated with Stereotactic Radiosurgery: A Retrospective Study from a Single Institution." 2025 RSS Scientific Meeting.
³ "Efficacy and Safety of Donut-Shaped Circumferential Spine CyberKnife Stereotactic Body Radiotherapy for Metastatic Spine Disease." 2025 RSS Scientific Meeting.
⁴ "Frameless Radiosurgery Is a Safe and Effective Treatment for Medically-Refractory Trigeminal Neuralgia in Elderly Patients." 2025 RSS Scientific Meeting.
⁵ "Efficacy and Safety of CyberKnife Stereotactic Radiosurgery for Occipital Condyle Metastasis." 2025 RSS Scientific Meeting.

SOURCE Accuray Incorporated